Skip to main content
OpenTrials
Completed

NCT Number: NCT04306731

Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Recurrent Urinary Tract Infection Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Infections Male Urogenital Diseases Urinary Tract Infections Urogenital Diseases Urologic Diseases

Age range

24 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

College of Medicine, University of Sulaimani

Sulaymaniyah, Kurdistan Region, 00964, Iraq

About this study

This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.

Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water.

In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 2 (two or more than two) UTI in the last 6 months
  • ≥ 3 (three or more than three) UTI in the last 12 months

Exclusion criteria

  • immunotherapy
  • radiotherapy
  • malignancy
  • steroids
  • chronic infections
  • chemotherapy
  • immunosuppressive drugs
  • anatomical abnormality of the urinary tract
  • surgical operation the urinary tract

Treatment and study plan

Nanotechnology Structured water Magnalife

Dietary Supplement

Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules

Other names: Magnalife, 5200250040466

Trimethoprim

Drug

Antibiotic

Other names: Proloprim

Ordinary bottled drinking water

Dietary Supplement

Placebo

Primary outcomes

  1. Recurrent Urinary Tract Infection

    Time frame: Twelve months

    Urinalysis by GUE (>10 white blood cells (WBC)/mm3 per high-power field (HPF) Urine culture (urinary pathogen of ≥105 colony-forming units (CFU) per mL)

Secondary outcomes

  1. Time to first recurrent UTI

    Time frame: Twelve months

    The time since the beginning of the study until the first recurrent UTI (days)

Sponsors and collaborators

Lead sponsor

University of Sulaimani

Other

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Use of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Mar 13, 2020
Registry last updated
Mar 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.